Login to Your Account



Neophore to prod cancer into neoantigen expression by targeting DNA mismatch repair

By Cormac Sheridan
Staff Writer

Wednesday, November 29, 2017

DUBLIN – The founders of the U.K.-listed gene editing technology firm Horizon Discovery plc, Alberto Bardelli and Chris Torrance, have re-emerged in a new startup that has a therapeutic focus.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription